These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 23218563)

  • 41. Paliperidone extended-release for schizophrenia: effects on symptoms and functioning in acutely ill patients with negative symptoms.
    Canuso CM; Bossie CA; Turkoz I; Alphs L
    Schizophr Res; 2009 Aug; 113(1):56-64. PubMed ID: 19560322
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Early- and delayed antipsychotic response and prediction of outcome in 528 severely impaired patients with schizophrenia treated with amisulpride.
    Lambert M; Schimmelmann BG; Naber D; Eich FX; Schulz H; Huber CG; Karow A
    Pharmacopsychiatry; 2009 Nov; 42(6):277-83. PubMed ID: 19924588
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
    Lane HY; Lin CH; Green MF; Hellemann G; Huang CC; Chen PW; Tun R; Chang YC; Tsai GE
    JAMA Psychiatry; 2013 Dec; 70(12):1267-75. PubMed ID: 24089054
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Remission after first-episode schizophrenia: results of a long-term follow-up.
    Üçok A; Serbest S; Kandemir PE
    Psychiatry Res; 2011 Aug; 189(1):33-7. PubMed ID: 21196051
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Time course of antipsychotic treatment response in schizophrenia: results from a naturalistic study in 280 patients.
    Jäger M; Riedel M; Obermeier M; Schennach-Wolff R; Seemüller F; Messer T; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Kühn KU; Lemke MR; Rüther E; Klingberg S; Gastpar M; Bottlender R; Möller HJ
    Schizophr Res; 2010 May; 118(1-3):183-8. PubMed ID: 20181461
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prediction of the significance in the improvement of depression symptoms of amisulpride in the treatment of schizophrenia: an 8-week case-control study.
    Wang G; Zhou B; Zheng L; Ni Y; Pan A
    Ann Palliat Med; 2020 Sep; 9(5):3481-3487. PubMed ID: 33065798
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Patient-based and clinician-based support for the remission criteria in schizophrenia.
    Docherty JP; Bossie CA; Lachaux B; Bouhours P; Zhu Y; Lasser R; Gharabawi GM
    Int Clin Psychopharmacol; 2007 Jan; 22(1):51-5. PubMed ID: 17159460
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Which role for amisulpride in rehabilitation of schizophrenic patients with acute exacerbation?
    Blin O
    Encephale; 2000 Oct; 26 Spec No 1():7-11. PubMed ID: 11294060
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adjunctive armodafinil for negative symptoms in adults with schizophrenia: a double-blind, placebo-controlled study.
    Kane JM; Yang R; Youakim JM
    Schizophr Res; 2012 Mar; 135(1-3):116-22. PubMed ID: 22178084
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Treatment of negative symptoms in schizophrenia with neuroleptics].
    Berner P; Küfferle B; Friedmann A; Grünberger J; Saletu B
    Encephale; 1989; 15(5):457-63. PubMed ID: 2574101
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prediction of Self-Report Cognitive Function for the Symptomatic Remission in Schizophrenia Treated with Amisulpride: a Multicenter, 8-Week Case-Control Study.
    Ji JW; Liu LY; Hao KR; Yu YL; Weng SZ; Wu JF; Huang RC
    Psychiatr Q; 2021 Sep; 92(3):935-945. PubMed ID: 33389476
    [TBL] [Abstract][Full Text] [Related]  

  • 52. On the concept of remission in schizophrenia.
    Leucht S; Beitinger R; Kissling W
    Psychopharmacology (Berl); 2007 Nov; 194(4):453-61. PubMed ID: 17618422
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identifying a system of predominant negative symptoms: Network analysis of three randomized clinical trials.
    Levine SZ; Leucht S
    Schizophr Res; 2016 Dec; 178(1-3):17-22. PubMed ID: 27617414
    [TBL] [Abstract][Full Text] [Related]  

  • 54. What could be learned from a decade with standardized remission criteria in schizophrenia spectrum disorders: An exploratory follow-up study.
    Johansson M; Hjärthag F; Helldin L
    Schizophr Res; 2018 May; 195():103-109. PubMed ID: 28899583
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Schizophrenia with onset after age 50 years. I: Phenomenology and risk factors.
    Brodaty H; Sachdev P; Rose N; Rylands K; Prenter L
    Br J Psychiatry; 1999 Nov; 175():410-5. PubMed ID: 10789270
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia.
    Marder SR; Alphs L; Anghelescu IG; Arango C; Barnes TR; Caers I; Daniel DG; Dunayevich E; Fleischhacker WW; Garibaldi G; Green MF; Harvey PD; Kahn RS; Kane JM; Keefe RS; Kinon B; Leucht S; Lindenmayer JP; Malhotra AK; Stauffer V; Umbricht D; Wesnes K; Kapur S; Rabinowitz J
    Schizophr Res; 2013 Nov; 150(2-3):328-33. PubMed ID: 24028744
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evolution of Presence of Predominant Negative Symptoms in Patients with Schizophrenia.
    Refaï T; Millier A; Toumi M
    Value Health; 2014 Nov; 17(7):A766. PubMed ID: 27202815
    [No Abstract]   [Full Text] [Related]  

  • 58. Impact of cognitive performance and negative symptoms on psychosocial functioning in Czech schizophrenia patients.
    Kalisova L; Michalec J; Dechterenko F; Silhan P; Hyza M; Chlebovcova M; Brenova M; Bezdicek O
    Schizophrenia (Heidelb); 2023 Jul; 9(1):43. PubMed ID: 37460587
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of Negative Symptom Domains and Other Clinical Characteristics on Functional Outcomes in Patients with Schizophrenia.
    Okada H; Hirano D; Taniguchi T
    Schizophr Res Treatment; 2021; 2021():8864352. PubMed ID: 33688435
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Single versus dual pathways to functional outcomes in schizophrenia: Role of negative symptoms and cognitive function.
    Okada H; Hirano D; Taniguchi T
    Schizophr Res Cogn; 2021 Mar; 23():100191. PubMed ID: 33204652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.